30-Day Mortality After Peptic Ulcer Perforation Among Users of Newer Selective Cox-2 Inhibitors and Traditional NSAIDs: A Population-Based Study
- 1 December 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 101 (12), 2704-2710
- https://doi.org/10.1111/j.1572-0241.2006.00825.x
Abstract
Nonsteroidal anti-inflammatory drug (NSAID) use is a strong risk factor for peptic ulcer perforation, yet little is known about the outcome of this condition among NSAID users. We examined 30-day mortality after peptic ulcer perforation associated with the use of traditional NSAIDs and newer selective cyclo-oxygenase-2 (COX-2) inhibitors. We conducted a cohort study of patients with the first hospitalization for peptic ulcer perforation, identified in discharge registries of three Danish counties between 1991 and 2003. Data on preadmission NSAID use, other ulcer-related drugs, and comorbidity were likewise from population-based registries. Mortality was ascertained from the Civil Registration System. We compared 30-day mortality in NSAID users and nonusers while adjusting for age, gender, comorbidity, previous uncomplicated peptic ulcer, and ulcer medication use. Of the 2,061 patients hospitalized with peptic ulcer perforation, 38% were current NSAID users. The 30-day mortality was 25% overall, and 35% among current NSAID users. Compared with never-use, the adjusted 30-day mortality rate ratios (MRRs) were 1.8 (95% CI 1.4–2.3) for current use of NSAIDs alone and 1.6 (95% CI 1.2–2.2) for current use combined with other ulcer-associated drugs. The mortality increase associated with the use of COX-2 inhibitors was similar to that of traditional NSAIDs: adjusted MRR for users of COX-2 inhibitors alone and in combination, 2.0 (1.3–3.1) and 1.4 (0.8–2.5), and for users of traditional NSAIDs alone or in combination, 1.7 (1.3–2.3) and 1.6 (1.2–2.3). Current use of NSAIDs, including COX-2 inhibitors, is associated with a poor prognosis for patients hospitalized with peptic ulcer perforation.Keywords
This publication has 32 references indexed in Scilit:
- Perforated peptic ulcer: use of pre‐admission oral glucocorticoids and 30‐day mortalityAlimentary Pharmacology & Therapeutics, 2005
- Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United KingdomPublished by Oxford University Press (OUP) ,2005
- Does Helicobacter pylori infection explain all socio‐economic differences in peptic ulcer incidence? Genetic and psychosocial markers for incident peptic ulcer disease in a large cohort of Danish adultsScandinavian Journal of Gastroenterology, 2004
- Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugsAmerican Journal Of Medicine, 2001
- Surgical Approach and Prognostic Factors after Peptic Ulcer PerforationThe European Journal of Surgery, 1999
- Selective Inhibitors of Cyclooxygenase-2: Are They Really Effective, Selective, and GI-safe?Journal of Clinical Gastroenterology, 1998
- Smoking and ulcer perforationGut, 1997
- Operative mortality after perforated peptic ulcerBritish Journal of Surgery, 1989
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Non-steroidal anti-inflammatory drugs and peptic ulcer perforation.Gut, 1985